Clinical Trial

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Study acronym: CaDAnCe-303
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab) in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to covalent Bruton tyrosine kinase inhibitor(s) (cBTKi).
Protocol Amendment History 2 changes
notable Trial sites reduced: 62 -> 56 locations 2026-08-11
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-30
Trial Details
NCT Number NCT06970743
Lead Sponsor BeOne Medicines
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 153 participants
Start Date 2025-05-29
Primary Completion 2029-11-30 (estimated)
Study Completion 2029-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-10